drugset
drugset / Trial / NCT05922709

A Clinical Trial of CS12192 in Healthy Subjects

NCT05922709 ↗

Phase 1 Completed 108 enrolled Chipscreen Biosciences, Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

The study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CS12192 after single or multiple oral administration, as well as the food effect on the pharmacokinetics in healthy subjects.

Timeline

Start
2023-07-20
Primary completion
2024-02-01
Completion
2024-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CS12192 Unknown 50 mg Oral
Subject CS12192 Unknown 150 mg Oral
Subject CS12192 Unknown 200 mg Oral
Subject CS12192 Unknown 300 mg Oral
Subject CS12192 Unknown 400 mg Oral
Subject CS12192 Unknown 600 mg Oral

Indications

No indication recorded.